CN109219594B - 吲哚啉类似物及其用途 - Google Patents

吲哚啉类似物及其用途 Download PDF

Info

Publication number
CN109219594B
CN109219594B CN201780034085.7A CN201780034085A CN109219594B CN 109219594 B CN109219594 B CN 109219594B CN 201780034085 A CN201780034085 A CN 201780034085A CN 109219594 B CN109219594 B CN 109219594B
Authority
CN
China
Prior art keywords
alkyl
group
compound
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780034085.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109219594A (zh
Inventor
斯蒂芬·E·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
Oncternal Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncternal Therapeutics Inc filed Critical Oncternal Therapeutics Inc
Publication of CN109219594A publication Critical patent/CN109219594A/zh
Application granted granted Critical
Publication of CN109219594B publication Critical patent/CN109219594B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780034085.7A 2016-03-31 2017-03-16 吲哚啉类似物及其用途 Active CN109219594B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662316156P 2016-03-31 2016-03-31
US62/316,156 2016-03-31
US201662417621P 2016-11-04 2016-11-04
US62/417,621 2016-11-04
PCT/US2017/022682 WO2017172368A1 (en) 2016-03-31 2017-03-16 Indoline analogs and uses thereof

Publications (2)

Publication Number Publication Date
CN109219594A CN109219594A (zh) 2019-01-15
CN109219594B true CN109219594B (zh) 2022-10-11

Family

ID=59960688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034085.7A Active CN109219594B (zh) 2016-03-31 2017-03-16 吲哚啉类似物及其用途

Country Status (10)

Country Link
US (3) US9822122B2 (https=)
EP (2) EP3795563B1 (https=)
JP (2) JP6864379B2 (https=)
KR (2) KR102375929B1 (https=)
CN (1) CN109219594B (https=)
AR (1) AR108010A1 (https=)
DK (1) DK3436434T3 (https=)
ES (1) ES2823190T3 (https=)
TW (2) TWI786723B (https=)
WO (1) WO2017172368A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108580B (zh) 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途
EP3795563B1 (en) * 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
TR202002324A2 (tr) * 2020-02-17 2021-08-23 Bahcesehir Ueniversitesi Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-3
CN111518086B (zh) * 2020-05-22 2021-08-06 广州医科大学 氧化吲哚-萘并呋喃衍生物及其制备方法、用途以及包含其的药物组合物、制剂
US20250361227A1 (en) * 2022-03-13 2025-11-27 University Of Virginia Patent Foundation Inhibitors of fli1 and erg
CN115850151A (zh) * 2022-11-25 2023-03-28 成都普康生物科技有限公司 一种席夫碱类似化合物及其合成方法、pi3k激酶抑制剂及其应用
CN115993455A (zh) * 2022-12-29 2023-04-21 南京医科大学康达学院 Rna结合蛋白nova2作为非小细胞肺癌转移标志物的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083326A2 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
CN104395288A (zh) * 2012-04-12 2015-03-04 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
WO2016057698A1 (en) * 2014-10-09 2016-04-14 Tokalas, Inc. Indolinone compounds and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3435034A (en) 1967-03-17 1969-03-25 Sandoz Ag Pyridazino(3,4-b)indoles
US3631177A (en) 1967-04-18 1971-12-28 Smith Kline French Lab 3-phenacyl-2-oxoindolines
US3592813A (en) 1967-04-18 1971-07-13 Smith Kline French Lab 3-phenyl-9h-pyridazino(3,4-b)indoles
US4376731A (en) 1978-01-31 1983-03-15 Boehringer Mannheim Gmbh 1-Aziridine carboxylic acid derivatives with immunostimulant activity
AU583793B2 (en) 1983-07-22 1989-05-11 Du Pont Pharmaceuticals Company Phenylquinolinecarboxylic acids and derivatives as antitumor agents
KR910700237A (ko) 1989-01-23 1991-03-14 리챠드 지. 워터맨 치환된 트리아졸, 그의 제조방법 및 살진균제로서 사용하기 위한 조성물
GB8909737D0 (en) 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
EP0613890A1 (en) 1993-02-28 1994-09-07 Nihon Nohyaku Co., Ltd. Novel triazole compound, process for preparing the same and antifungal agent containing the same
CA2190708A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
AU7108398A (en) 1997-04-16 1998-11-11 Abbott Laboratories 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors
EP1135123B1 (en) 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030114666A1 (en) 2001-06-19 2003-06-19 Ellsworth Edmund Lee Antibacterial agents
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
EP1753754A1 (en) 2004-05-25 2007-02-21 AstraZeneca AB 3- '4- {6-substituted alkanoyl) pyridin-3-yl} -3-phenyl! -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
JP2008500318A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
EP1871766A4 (en) 2005-03-30 2010-07-21 Dae Woong Pharma TRIAZONE DERIVATIVES WITH ANTIPILY EFFECT
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
CA2610588A1 (en) 2005-06-10 2006-12-21 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2620878A1 (en) 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
CA2679657A1 (en) 2007-03-02 2008-09-12 Micurx Pharmaceuticals, Inc. Antimicrobial heterocyclic compounds for treatment of bacterial infections
MX2009011281A (es) 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
WO2010019910A1 (en) 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
WO2010033643A2 (en) 2008-09-17 2010-03-25 Burnham Institute For Medical Research Small molecule compounds for stem cell differentiation
US20110218155A1 (en) 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US8710068B2 (en) * 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
CA2807815C (en) 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
IN2014MN00093A (https=) 2011-06-19 2015-06-19 Viamet Pharmaceuticals Inc
CN102516152B (zh) 2011-12-12 2014-12-10 华东师范大学 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
WO2013144224A1 (en) 2012-03-27 2013-10-03 Syngenta Participations Ag Acetylenic microbiocides
US20130259927A1 (en) 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
AU2013305759C1 (en) 2012-08-23 2018-01-18 Janssen Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014152144A1 (en) 2013-03-15 2014-09-25 Acadia Pharmaceuticals Inc. Muscarinic agonists
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
AU2014340398A1 (en) 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer
CN105960239A (zh) 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
WO2015082583A1 (en) 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
SG11201607392SA (en) 2014-03-07 2016-10-28 Bristol Myers Squibb Co Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
CA2961356C (en) 2014-09-15 2023-03-07 Plexxikon Inc. Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083326A2 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
CN104395288A (zh) * 2012-04-12 2015-03-04 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
WO2016057698A1 (en) * 2014-10-09 2016-04-14 Tokalas, Inc. Indolinone compounds and uses thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CAS RN: 312498-36-5;CHEMCATS;《DATABASE REGISTRY》;20010102 *
CAS RN: 340220-38-4;CHEMCATS;《Database Registry》;20010610 *
CAS RN: 371224-67-8;CHEMCATS;《DATABASE REGISTRY》;20011121 *
CAS RN: 832093-84-2;CHEMCATS;《DATABASE REGISTRY》;20050216 *
CAS RN: 846583-15-1;CHEMCATS;《DATABASE REGISTRY》;20050322 *
CAS RN: 908808-85-5;CHEMCATS;《DATABASE REGISTRY》;20060927 *
CAS RN: 908809-07-4;CHEMCATS;《DATABASE REGISTRY》;20060927 *
CAS RN: 908809-10-9;CHEMCATS;《Database Registry》;20060927 *
CAS RN:908809-06-3;CHEMCATS;《DATABASE REGISTRY》;20060927 *
Highly efficient regioselective synthesis of pyrroles via a tandem enamine formation–Michael addition–cyclization sequence under catalyst- and solvent-free conditions;Thavaraj Vivekanand等;《Green Chemistry》;20150417;第17卷;Supporting Information S2-S3页 *
Ordered short channel mesoporous silica modified with 1,3,5-triazine–piperazine as a versatile recyclable basic catalyst for cross-aldol, Knoevenagel and conjugate addition reactions with isatins;Naveen Gupta等;《RSC Advances》;20150205;第5卷;table 3 entry 15 *
Synthesis and Structure−Activity Relationship Studies of Small Molecule Disruptors of EWS-FLI1 Interactions in Ewing’s Sarcoma;Perrer N. Tosso等;《Journal of Medicinal Chemistry》;20141128;第57卷;全文 *

Also Published As

Publication number Publication date
US10351569B2 (en) 2019-07-16
TW202140492A (zh) 2021-11-01
ES2823190T3 (es) 2021-05-06
US20190337951A1 (en) 2019-11-07
EP3795563B1 (en) 2024-07-17
EP3795563A1 (en) 2021-03-24
JP7269668B2 (ja) 2023-05-09
TWI793070B (zh) 2023-02-21
KR102514814B1 (ko) 2023-03-27
US9822122B2 (en) 2017-11-21
EP3436434B1 (en) 2020-07-08
EP3436434A4 (en) 2019-08-28
DK3436434T3 (da) 2020-09-21
KR20180123569A (ko) 2018-11-16
TWI786723B (zh) 2022-12-11
KR20220038529A (ko) 2022-03-28
US10711008B2 (en) 2020-07-14
AR108010A1 (es) 2018-07-04
US20170283420A1 (en) 2017-10-05
JP6864379B2 (ja) 2021-04-28
CN109219594A (zh) 2019-01-15
US20170349600A1 (en) 2017-12-07
EP3436434A1 (en) 2019-02-06
JP2019510069A (ja) 2019-04-11
TW201738209A (zh) 2017-11-01
JP2021102643A (ja) 2021-07-15
KR102375929B1 (ko) 2022-03-16
WO2017172368A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CN109219594B (zh) 吲哚啉类似物及其用途
CN107011242B (zh) 用于治疗尤文肉瘤家族肿瘤的方法和组合物
CN107108580B (zh) 吲哚酮化合物及其用途
HK40029898A (en) Indolone compounds and uses thereof
HK1236930A1 (en) Indolinone compounds and uses thereof
HK1242313A1 (en) Methods and compositions for treating ewing's sarcoma family of tumors
HK1236930B (zh) 吲哚酮化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant